Introduction
============

Microphthalmia and coloboma are important cause of congenital blindness, with a prevalence at 1.9--3.5/10,000 live births \[[@r1],[@r2]\]. Microphthalmia and coloboma may be isolated or syndromic with the extraocular phenotype in one or both eyes. The disease exhibits diverse patterns of genetic inheritance, and the severity is variable, due to the genetic heterogeneity of the ocular malformation \[[@r3]-[@r8]\]. Mutations in several genes have been reported in patients with microphthalmia and/or coloboma \[[@r3],[@r9]-[@r14]\], including *BMP4* (OMIM [112262](http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=112262)), *VSX2* (*CHX10*; OMIM [142993](http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=142993)), *CRYBA4* (OMIM [123631](http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=123631)), *OTX2* (OMIM [600037](http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=600037)), *RAX* (OMIM [601881](http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=601881)), *SIX6* (OMIM [606326](http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=606326)), and *SOX2* (OMIM [184429](http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=184429)). Of these, mutations in *SOX2* account for about 10% of microphthalmia, anophthalmia, and coloboma \[[@r3],[@r15],[@r16]\]. However, mutations in *VSX2*, *CRYBA4*, *OTX2*, and *RAX* have been detected in about 2%--3% patients with microphthalmia, anophthalmia, and coloboma \[[@r10],[@r11],[@r15],[@r17],[@r18]\]. Mutations in *SIX3* and *GDF6* have been identified only in a few cases \[[@r19],[@r20]\]. Recently, mutations in *BMP4* mutations have been detected in patients with anophthalmia-microphthalmia \[[@r9]\]. In addition, knockout of LRP6 in mice resulted in microphthalmia and coloboma, but has not yet been reported in humans \[[@r21]\].

Because most of these genes were usually studied individually, and mutation analysis of Chinese patients is rare so far, we screened 32 unrelated patients with microphthalmia and/or coloboma for mutations in ten related genes, including *BMP4*, *VSX2*, *CRYBA4*, *GDF6*, *OTX2*, *RAX*, *SIX3*, *SIX6*, *SOX2*, and *LRP6*, through sequencing analysis of the coding and adjacent intronic regions of the ten genes.

Methods
=======

Patients and controls
---------------------

Thirty-two unrelated patients were recruited from our Pediatric and Genetic Eye Clinic, Zhongshan Ophthalmic Center. Clinical diagnoses of the 32 patients were microphthalmia (nine cases) and uveal coloboma (23 cases). Diagnosis of microphthalmia was based on criteria previously described \[[@r15]\], that is, a corneal diameter less than 10 mm and an axial length less than 20 mm. Of the nine cases with microphthalmia, eight met the criteria but one did not, although a small cornea and short axial length were recorded (details in results). On the other hand, the inclusion criteria for uveal coloboma were 1) congenital cleft in the inferior part of the iris and/or choroid ([Figure 1](#f1){ref-type="fig"}) and 2) exclusion of aniridia or macular uveal coloboma. Besides this, an internal control sample for optimizing PCR and sequencing conditions was from a girl with aniridia and an identified PAX6 mutation. Furthermore, 96 unrelated controls were collected from normal volunteers. A previously established procedure was used for collecting subjects and obtaining informed consent \[[@r22]\]. This study was approved by the Institutional Review Board of Zhongshan Ophthalmic Center, China. Genomic DNA was prepared from venous blood from each participating individual \[[@r23]\].

![Uveal coloboma. **A** and **B** demonstrate iris coloboma (**A**) and choroid coloboma involving the optic disc (**B**). **C** and **D** show inferior choroid coloboma. (**D** did not align well with **C**).](mv-v15-2911-f1){#f1}

Mutation detection
------------------

PCR was used to amplify the coding exons and adjacent intronic sequences of the ten genes. Reference sequences for the ten genes are listed in [Table 1](#t1){ref-type="table"}. The primer sequences used to amplify the coding exons of the ten genes are listed in [Table 2](#t2){ref-type="table"}. The PCR products from individual exons from each individual were sequenced with the ABI BigDye Terminator cycle sequencing kit v3.1 (Applied Biosystems, Foster City, CA) and an ABI 3100 Genetic Analyzer (Applied Biosystems). Sequencing results and consensus sequences from the NCBI human genome database were compared by using the SeqManII program of the Lasergene package (DNAstar Inc., Madison, WI). Each mutation was confirmed by bidirectional sequencing. Mutation description followed the nomenclature recommended by the Human Genomic Variation Society.

###### Genomic information of the 10 genes referred in this study.

  Gene       Genomic DNA                                                        mRNA                                                                   Protein
  ---------- ------------------------------------------------------------------ ---------------------------------------------------------------------- ------------------------------------------------------------------------------------------------
  *BMP4*     [NC_000014.8](http://www.ncbi.nlm.nih.gov/nuccore/NC_000014.8)     [NM_001202.3](http://www.ncbi.nlm.nih.gov/nuccore/NM_001202.3)         [NP_001193.2](http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=protein&val=NP_001193.2)
  *VSX2*     [NC_000014.8](http://www.ncbi.nlm.nih.gov/nuccore/NC_000014.8)     [NM_182894.2](http://www.ncbi.nlm.nih.gov/nuccore/NM_182894.2)         [NP_878314.1](http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=protein&val=NP_878314.1)
  *CRYBA4*   [NC_000022.10](http://www.ncbi.nlm.nih.gov/nuccore/NC_000022.10)   [NM_001886.2](http://www.ncbi.nlm.nih.gov/nuccore/NM_001886.2)         [NP_001877.1](http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=protein&val=NP_001877.1)
  *GDF6*     [NC_000008.10](http://www.ncbi.nlm.nih.gov/nuccore/NC_000008.10)   [NM_001001557.1](http://www.ncbi.nlm.nih.gov/nuccore/NM_001001557.1)   [NP_001001557.1](http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=protein&val=NP_001001557.1)
  *OTX2*     [NC_000014.8](http://www.ncbi.nlm.nih.gov/nuccore/NC_000014.8)     [NM_021728.2](http://www.ncbi.nlm.nih.gov/nuccore/NM_021728.2)         [NP_068374.1](http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=protein&val=NP_068374.1)
  *RAX*      [NC_000018.9](http://www.ncbi.nlm.nih.gov/nuccore/NC_000018.9)     [NM_013435.2](http://www.ncbi.nlm.nih.gov/nuccore/NM_013435.2)         [NP_038463.2](http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=protein&val=NP_038463.2)
  *SIX3*     [NC_000002.11](http://www.ncbi.nlm.nih.gov/nuccore/NC_000002.11)   [NM_005413.2](http://www.ncbi.nlm.nih.gov/nuccore/NM_005413.2)         [NP_005404.1](http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=protein&val=NP_005404.1)
  *SIX6*     [NC_000014.8](http://www.ncbi.nlm.nih.gov/nuccore/NC_000014.8)     [NM_007374.2](http://www.ncbi.nlm.nih.gov/nuccore/NM_007374.2)         [NP_031400.2](http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=protein&val=NP_031400.2)
  *SOX2*     [NC_000003.11](http://www.ncbi.nlm.nih.gov/nuccore/NC_000003.11)   [NM_003106.2](http://www.ncbi.nlm.nih.gov/nuccore/NM_003106.2)         [NP_003097.1](http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=protein&val=NP_003097.1)
  *LRP6*     [NC_000012.11](http://www.ncbi.nlm.nih.gov/nuccore/NC_000012.11)   [NM_002336.2](http://www.ncbi.nlm.nih.gov/nuccore/NM_002336.2)         [NP_002327.2](http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=protein&val=NP_002327.2)

The genomic DNA information was based on NCBI human genome build 36.3.

###### Primers used for polymerase chain reaction amplification and sequencing of *BMP4*, *VSX2*, *CRYBA4*, *GDF6*, *OTX2*, *RAX*, *SIX3*, *SIX6*, *SOX2*, and *LRP6*.

  **Gene**   **Exon**    **Primer sequence (5\'-3\')**   **Amplicon size (bp)**   **Annealing temperature (°C)**
  ---------- ----------- ------------------------------- ------------------------ --------------------------------
  *BMP4*     3-F         CCATCTTGCCCCTCCATTTCTA          570                      65
             3-R         CTTCTTCCCCAGGGCTTTCACT                                    
             4a-F        TGCTTATTTTCCCCCAGTAGGT          704                      62
             4a-R        GGCGCCGGCAGTTCTTATTCTT                                    
             4b-F        GGGCCAGCATGTCAGGATTAGC          575                      62
             4b-R        TGTGGGTGAGTGGATGGGAACG                                    
             RFLP-F      CGGGAGAAGCAGCCAAACTATG          237                      65
             RFLP-R      CTTCTTCCTGGCCCGCTGTGAG                                    
  *VSX2*     1-F         AGGGGGCACCTGGGACCAAC            586                      72
             1-R         CCCGGCCTGGCAGGAACTTT                                      
             2-F         CGGCGCGGGAGAGGTCAG              427                      66
             2-R         GCAGATTCCGCCAAACAAC                                       
             3-F         TGCCCAGGAGACACAGAGG             347                      64
             3-R         ACATGATCATAGGCAAGCACA                                     
             4-F         AGGACGCCCTGCTGGAGAAA            380                      68
             4-R         CCAAGTGCCCCTGCCTCAA                                       
             5-F         CTGCGGTGTGGGGAGTAAG             574                      65
             5-R         GTGGGGAACAGGGAGGATG                                       
  *CRYBA4*   2-F         ACTCCTGGACTCCCTATGTG            319                      60
             2-R         ATTCAACCTCCCTGTATGTG                                      
             3-F         TCTTGCCTTCCTGGCTCCTG            430                      62
             3-R         TGCGCAACCTGCATAATCTT                                      
             4-F         CCCCTGAATGGTTGTGACT             396                      62
             4-R         AACCGAGGCTTGGAGAGGAA                                      
             5-F         AAGGGCAAATGGCAAGGTT             415                      62
             5-R         TGGGCATCAGAGCACAAAAG                                      
  *GDF6*     1-F         GGCGGGGCCGGGGTTTGT              635                      72
             1-R         TAGCCTCCAGCGGGAACAGC                                      
             2a-F        CGGCCGACCTGCCCCCACTC            504                      70
             2a-R        CCGGCCGAAGCCCAGACTCC                                      
             2b-F        GCCGGCCGGCTGGGAAGTCT            557                      70
             2b-R        GCGAGCGCAGCGGGAAGTCG                                      
             2c-F        GCGCACGGCCTTCGCCAGTC            469                      70
             2c-R        CCAGCGCCAGCTTCCTCCTC                                      
  *OTX2*     3-F         TTTGCTTTGCCCTTAGTTCC            424                      62
             3-R         CCCTGTTCTCTGCTTGGTCA                                      
             4-F         ACGGTGGGGAGAGCATTGGT            445                      62
             4-R         CCTGGCCCCTTAGTGAGTGA                                      
             5a-F        CTGCCCATGTAGGATAGATT            440                      61
             5a-R        ATGCCCCCAAAGTAGGAAGT                                      
             5b-F        GCTTCCATCTCCCCACTGTC            562                      61
             5b-R        GGCCCTTCGTTTTTCCTTCT                                      
  *RAX*      1-F         TTCGCCCGCGGAGCTTGACCT           527                      66
             1-R         CCCCAACCCCGCGCCCAGTT                                      
             2-F         CCATCGCCGCCCTCACCA              522                      66
             2-R         ACTCTGGGCATGCCAAGTCG                                      
             3-F         TTGAGGGGGACGGAGTGGAG            716                      69
             3-R         GCAGGCGACAGGGAAAGAGG                                      
  *SIX3*     1a-F        TCATCGCCCCTCTCCTCCTCTT          398                      70
             1a-R        GCCGCTCGATGTCGCCCGTCTC                                    
             1b-F        CGGCGGCGGCGGCTCCAG              387                      72
             1b-R        CGCACGCGGTACTTGTCCAC                                      
             1c-F        GCGTGCGAGGCCATCAACAA            552                      65
             1c-R        CACGGCTTCCCTGGCTCTCA                                      
             2-F         GCTCGGGTTCTGCCTCTC              457                      64
             2-R         TCGGTTTGTTCTGGGGATGG                                      
  *SIX6*     1a-F        TGTGTCCCGCTGCCCCAATC            514                      65
             1a-R        TTCTGTTCGCCGTCCCAAATG                                     
             1b-F        CCTTTCACGGTGGCAACTAC            514                      65
             1b-R        GACAGACCGCGCTCCCAACTC                                     
             2-F         CGCCTTGCCGAGTAATCCT             447                      70
             2-R         AGCCCGCGGGTCCCTGGTCAC                                     
             HA-SSCP-F   TCGCCTTAACTGCTGGGGTCTT          253                      67
             HA-SSCP-R   AGTGGCCGCCTTGCTGGATA                                      
  *SOX2*     1-F         CGCCTCCCCTCCTCCTCTC             443                      68
             1-R         CGCCGGGGCCGGTATTTAT                                       
             2-F         GGGCGCCGAGTGGAAACTT             473                      65
             2-R         GGGTGCCCTGCTGCGAGTA                                       
             3-F         CACGGCGCAGCGCAGATGC             459                      65
             3-R         TTTGCACCCCTCCCATTTC                                       
  *LRP6*     1-F         CTCCTCGCCTCCCCCACTTCTG          279                      72
             1-R         CTGCTCCCGGGCCCCTTTCTCT                                    
             2-F         ATTTTCGACAGTCTTTGCTCAC          589                      65
             2-R         TTCTTTTCTCATAGGGGTCAGG                                    
             3-F         GCGCGGCCTGAGCTTTCTTTA           410                      64
             3-R         CTTCTTCCCCTCTGGCACTTAG                                    
             4-F         ATTTTAATGGGAGAGGTGACG           395                      60
             4-R         TTTATTCCCGCCAACTATCTTT                                    
             5-F         AATTTTGGCTTATCACAGTT            330                      58
             5-R         GGTCTCCCAAAGCAGTAT                                        
             6-F         TTTTATATTTATTTTTCAGTTC          575                      50
             6-R         ATGTTATCTTAGTCAATGTTTT                                    
             7-F         GGGATGGATCTCACCTTTAG            478                      58
             7-R         GATCAGCAGCCATTTCTCA                                       
             8-F         GGGGGAAAAGTGGTCAAA              538                      56
             8-R         GGGGGCAGTAAAGAAGGT                                        
             9-F         TGGGAGCAAGACATAATCATAG          690                      64
             9-R         TGGCACGCACCTGTAGTCCT                                      
             10-F        GGATCCTCTTGCCCCTGACA            560                      62
             10-R        TAACCCATTCCCCTCTTTCTTC                                    
             11-F        ATTGTAGCCGTGATTTTGTTTA          577                      58
             11-R        TCAGGAGTATCTAGGGAGTTAT                                    
             12-F        AAGCATGGGGTCAGAAGATAGA          777                      62
             12-R        AAAGTGCTGGGTTACGGACATA                                    
             13-F        TGAGGGCATGCCAAAGAAT             499                      58
             13-R        AATAAGCTACCAGGTCCAGAAT                                    
             14-F        GTGTGCCCATGTAGGTGTAAGC          511                      64
             14-R        TAGTGGCCCAGGAAAGAAAGTC                                    
             15-F        CCGCCTCAGTCTCCCAAAGT            491                      68
             15-R        TGCCAAGAAATGTGCCAAAAAC                                    
             16-F        TATCTAGTTTATTGGCTGTT            506                      52
             16-R        CTAAAAGTGCATGAAAGTCT                                      
             17-F        AAGCTGATTATACATTTGATTT          403                      64
             17-R        GGGCAGGGTGGCAGAGAA                                        
             18-F        TAAAGGAAGTAATGTGAAAACC          521                      58
             18-R        TGAAAAACCCCAACTGAC                                        
             19-F        AGGCACCTTTTGATTCTTG             495                      61
             19-R        CGCCCGGCTGATTTCTATGTAT                                    
             20-F        TTCAGGGCGTGGTATGTATGT           578                      58
             20-R        TATCTAAGGCCTTCTGTGTAAA                                    
             21-F        AGCTATTCTTGGCCTTGTTCTA          508                      61
             21-R        AGTCCTTTGAGCCTTTTATGC                                     
             22-F        TTTTAGCCATGATGAGGTCTTA          373                      64
             22-R        GGGGCTATATCAGGTCCACAAC                                    
             23-F        GAAAATTGCCTCTTGGTCTGTG          550                      65
             23-R        TGGTCTGCCTCATCCTTCTCTA                                    

Heteroduplex-single strand conformation polymorphism analysis
-------------------------------------------------------------

The c.608G\>A variation detected in *SIX6* was further evaluated in 96 normal controls by heteroduplex-single strand conformation polymorphism (HA-SSCP) analysis, as previously described \[[@r24]\], using an extra pair of primers ([Table 2](#t2){ref-type="table"}). Briefly, PCR products were mixed with an equal volume of formamide dye loading buffer. Then 1--4 μl of the mixture was loaded on 40 cm×30 cm×1 mm 8% polyacrylamide gels containing 10% glycerol. The DNA samples were separated by electrophoresis for 8--9 h at room temperature without temperature control. The DNA fragments were visualized by silver staining.

Restriction fragment-length polymorphism analysis
-------------------------------------------------

The variation detected in *BMP4* c.751C\>T was further evaluated in available family members, as well as in 96 normal controls, by restriction fragment-length polymorphism (RFLP) analysis using an extra pair of primers ([Table 2](#t2){ref-type="table"}). Since the c.751C\>T variation in *BMP4* erased an enzyme recognition site of CviAII, wild amplicons were digested into four fragments (78, 76, 68, and 15 bp) while the variant amplicons were cut into three pieces (154, 68, and 15 bp).

Results
=======

Mutation analysis
-----------------

Eighteen nucleotide substitutions ([Table 3](#t3){ref-type="table"}), including two novel missense variations, eight known SNPs, and eight new synonymous changes, were detected upon complete sequencing analysis of the coding exons and the adjacent intronic regions of *BMP4*, *VSX2*, *CRYBA4*, *GDF6*, *OTX2*, *RAX*, *SIX3*, *SIX6*, *SOX2*, and *LRP6*. Of the two novel heterozygous missense variations, one was c.608G\>A (p.R203Q) in *SIX6* and the other was c.751C\>T (p.H251Y) in *BMP4*.

###### Sequence variations found in *BMP4*, *CRYBA4*, *GDF6*, *LRP6*, *RAX*, SIX3, *SIX6*, *SOX2*, and *VSX2*.

  **Gene**   **Exon**   **Sequence variation**   **Amino acid change**   **Patient number**    **Result**
  ---------- ---------- ------------------------ ----------------------- --------------------- -----------------------------------------------------------------------
  BMP4       4          c.455T\>C                S155S                   TT:TC:CC = 19:10:3    [rs17563](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=17563)
             4          c.751C\>T                H251Y                   1                     Novel variation
  CRYBA4     Intron 2   c.40-71C\>T              No splice site change   2                     [rs2071860](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2071860)
             Intron 3   c.158+58C\>T             No splice site change   3                     [rs58707060](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=58707060)
             Intron 3   c.159-20A\>G             No splice site change   AA:A/G:GG = 8:19:13   [rs59023621](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=59023621)
             Intron 5   c.444-18g\>a             No splice site change   4                      
  GDF6       1          c.255G\>T                P85P                    1                      
  LRP6       5          c.867C\>T                D289D                   1                      
             11         c.2450C\>G               S817C                   1                     [rs2302686](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2302686)
             14         c.3184G\>A               V1062I                  5                     [rs2302685](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2302685)
  RAX        1          c.132C\>A                D44E                    6                     [rs2271733](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=2271733)
             3          c.882A\>G                Q294Q                   4                      
  SIX3       1          c.90G\>T                 A30A                    4                      
  SIX6       1          c.421C\>A                N141K                   7                     [rs33912345](http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=33912345)
             2          c.637C\>T                P213S                   1                      
             2          c.608G\>A                R203Q                   1                     Novel variation
  SOX2       1          c.573A\>G                A191A                   1                      
  VSX2       4          c.750G\>A                P250P                   1                      

No variation was identified in *OTX2*.

For internal quality control, the c.608G\>A variation in *SIX6* was detected in an individual when her sample was used to optimize the experimental condition, but was not present in 96 unrelated normal controls. She was a three-month-old girl who had typical congenital aniridia with normal cornea size (a bilateral cornea diameter of 10 mm at the age of 3 months, within the normal range at this age) and a previously determined novel *PAX6* mutation (c.718C\>T, p.R240X). This suggested that the c.608G\>A variation in *SIX6* did not play additive effect and, therefore, might not be causative.

The c.751C\>T variation in *BMP4* was detected in a proband suspected for microphthalmia ([Figure 2](#f2){ref-type="fig"}), but was not detected in 96 unrelated normal controls. BMP4 alignment among six different species showed that the residue at 251 of BMP4 protein is highly conserved ([Figure 2C](#f2){ref-type="fig"}). This ocular biometry measurement did not fully meet the criteria for micropthalmia, but did demonstrate an obviously small cornea and short axial length ([Table 4](#t4){ref-type="table"}). Besides this, he had bilateral corneal opacities, multiple pupils, an persistent iris membrane, and anterior pole cataract ([Figure 2D-E](#f2){ref-type="fig"}). Unexpectedly, the c.751C\>T variation was also present in his healthy brother with a normal ocular phenotype, including a normal anterior segment and normal axial length ([Table 4](#t4){ref-type="table"} and [Figure 2F-G](#f2){ref-type="fig"}). His sister (II:1 in [Figure 2](#f2){ref-type="fig"}) and parents (I:1 and I:2 in [Figure 2](#f2){ref-type="fig"}) were reported to be normal, but were unavailable to have ocular biometry. The variation was present in both the proband and in his healthy brother, and at least one of the parents (in whom only the proband had an abnormal ocular phenotype).

![*BMP4* variation and associated phenotype. **A**: Sequence chromatogram demonstrated the c.751C\>T variation in *BMP4* from the patient (left) and normal sequence from a control (right). **B**: The c.751C\>T variation in *BMP4* detected by PCR-RFLP analysis (P: PCR products \[237 bp\] and M: marker, showing 100 bp and 250 bp, respectively; the plus sign \[+\] indicates CviAII-digested-products with heterozygous c.751C\>T variation; the minus sign \[-\] indicates CviAII-digested products without the c.751C\>T variation). **C**: Protein alignment of human BMP4 (residues 231--271) with other BMP4 orthologs from cattle, cock, mouse, rat, and zebra fish. **D** and **E**: Ocular phenotype of the proband showing bilateral microcornea, corneal opacities, multiple pupils, persistent iris membrane adhering to cornea (right eye) or lens capsule (left eye), and anterior pole cataract (right eye). **F** and **G**: Normal ocular phenotype of the proband's healthy brother, which also carried the heterozygous c.751C\>T variation in *BMP4*.](mv-v15-2911-f2){#f2}

###### Ocular biometry of the individuals with the *BMP4* mutation.

  **Individual**    **Eye**   **Best visual acuity**   **Cornea diameter (mm)**   **Anterior chamber depth (mm)**   **Ocular length (mm)**
  ----------------- --------- ------------------------ -------------------------- --------------------------------- ------------------------
  Proband           OD        0.5                      10.7                       2.25                              20.28
                    OS        0.3                      10.8                       2.23                              20.13
  Healthy brother   OD        1.5                      11.4                       3.39                              22.78
                    OS        1.5                      11.6                       3.32                              22.74

Ocular biometry was measured by using IOL Master V5 (Carl Zeiss Meditec AG, Jena, Germany). The proband had a small cornea and short axial length. His brother had normal ocular biometry (normal range in Chinese adults: 12.12±0.40 mm for cornea diameter and 23.60±0.79 mm for axial length).

Discussion
==========

Normal development of the eye involves a complex process. Both genetic and environmental factors may play roles in the malformation of the eye. Although mutations in several genes have been detected in patients with microphthalmia or coloboma, such mutations are only detected in a small percentage of patients. In addition, these genes have not been analyzed simultaneously in any cohort of microphthalmia and/or coloboma cases.

In the present study, ten genes previously reported to be responsible for microphthalmia and/or uveal coloboma were analyzed simultaneously in 32 Chinese patients with microphthalmia and/or uveal coloboma. Upon complete screening of the coding exons and adjacent intronic regions of *BMP4*, *VSX2*, *CRYBA4*, *GDF6*, *OTX2*, *RAX*, *SIX3*, *SIX6*, *SOX2*, and *LRP6*, no causative mutation was detected. This is the first systemic analysis of all ten genes in a series of microphthalmia and coloboma patients, and is the first analysis of most such genes in Chinese patients. The results suggest that the genetic cause of microphthalmia and uveal coloboma in Chinese is largely unknown.

*SIX6* encodes a nuclear homeoprotein and is expressed in the developing retina, optic stalk, and the hypothalamic and pituitary regions. Interstitial deletions at 14q22.3-q23, where *SIX6* is located, were found in three patients with bilateral anophthalmia, absence of the optic nerve, and chiasm and pituitary abnormalities \[[@r25]\]. Gallardo et al. \[[@r14]\] identified a heterozygous c.493A\>G (p.T165A) variation in SIX6 in a patient with bilateral microphthalmia, cataract, and nystagmus from among a series of 73 patients with syndromic or nonsyndromic sporadic clinical anophthalmia and microphthalmia. However, this variation was also present in the healthy father, although it was not detected in more than 160 chromosomes from normal individuals. Aijaz et al. \[[@r26]\] did not find *SIX6* mutation 173 patients with microphthalmia, anophthalmia, and coloboma. In that study, the c.608G\>A variation in *SIX6* was detected in an individual with typical congenital aniridia and a previously determined *PAX6* mutation (c.718C\>T, p.R240X). Overall, there is no firm evidence that mutation in *SIX6* alone can cause microphthalmia, anophthalmia, or coloboma.

The *BMP4* gene product is a regulatory molecule functioning in mesoderm induction, tooth development, limb formation, bone induction, and fracture repair. *BMP4* is located in 14q22-q23, where recurrent interstitial deletions have been associated with anophthalmia-microphthalmia \[[@r9]\]. Bakrania et al. \[[@r9]\] identified a c.226del2 (p.S76fs104X) mutation at *BMP4* in a family whose carrier members had various phenotypes, including anophthalmia-microphthalmia, retinal dystrophy, myopia, brain anomalies, and polydactyly. In another family, a c.278A\>G (p.E93G) mutation was found. However, these two mutations were also present in one of the phenotypically normal parents from each family \[[@r9]\]. On the other hand, three missense mutations in *BMP4* were reported in patients with orofacial cleft 11 (OMIM [600625](http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=600625)) \[[@r27]\]. In that study, the c.751C\>T variation in *BMP4* was present in a patient with microphthalmia, as well as in his healthy brother, and possibly in one of his normal parents. Therefore, further study is needed to reveal the role of *BMP4* in micropthalmia.

In summary, the c.608G\>A variation in *SIX6* and the c.751C\>T variation in *BMP4* might be reported as causative mutations if the *SIX6* c.608G\>A variation is detected in a patient without a confirmed genetic basis, and if cosegregation analysis is not performed for the *BMP4* c.751C\>T variation. Additional studies are expected to validate the association of microphthalmia and uveal coloboma with mutations in *SIX6* and *BMP4*. Great care is needed in making mutation--disease associations based on marginal evidence, especially for those genes with only a few identified mutations. Future genetic analyses of additional patients, as well as of other candidate genes, may enrich our understanding of the molecular basis of microphthalmia and uveal coloboma, as well as of the genotype--phenotype correlation.
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